Search results
Produce a new standalone guideline on uncontrolled asthma that includes guidance on pharmacological management (specifically biologics), assessment, phenotyping, high-risk patients, biomarkers and monitoring (replacing the existing sections 7 and 10).
Guidelines Network (SIGN) agreed to jointly produce a comprehensive new asthma guideline, both having previously published guidance on asthma. The original BTS guideline dated back to 1990 and the SIGN guidelines to 1996. Both organisations recognised the need to develop the new guideline using evidence-based methodology explicitly.
This Quick Reference Guide provides a summary of the main recommendations in SIGN 158 British guideline on the management of asthma. Recommendations are graded A B C D to indicate the strength of the supporting evidence.
BTS/SIGN British Guideline on the Management of Asthma. BTS/SIGN/NICE joint Guideline for the Diagnosis, Monitoring and Management of Chronic Asthma. The draft guideline, evidence reviews and information on the consultation on the guideline is here.
SIGN guidelines are produced using a standard methodology that has been equality impact assessed to ensure that these equality aims are addressed in every guideline. This methodology is set out in the current version of SIGN 50, our guideline manual, which can be found at www.sign.ac.uk/guidelines/fulltext/50/index.html.
This Quick Reference Guide provides a summary of the main recommendations in SIGN 153 British guideline on the management of asthma. Recommendations are graded A B C D to indicate the strength of the supporting evidence.
This is a new collaborative guideline produced by BTS, NICE and SIGN. It updates NICE guideline 80 (published November 2017) and parts of BTS/SIGN guideline (SIGN 158, published July 2019). Who is it for? • GPs and practice nurses • Healthcare professionals in secondary care and tertiary asthma services • Commissioners and providers
